A large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2piBwsF
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2piBwsF